Nova Eye MedicalELXMF -0.03%55 PS Ratio is 0.18 as of Jul. 01, 2026, which is 89% below its 10-year median of 1.65. GuruFocus rates ELXMF with a GF Score™ of 55/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 83.23% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nova Eye Medical's share price is $0.01431.
Nova Eye Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.08. Hence, Nova Eye Medical's PS Ratio for today is 0.18.
Good Sign:
Nova Eye Medical Ltd stock PS Ratio (=0.89) is close to 10-year low of 0.84.
The historical rank and industry rank for Nova Eye Medical's PS Ratio or its related term are showing as below:
ELXMF'
s PS Ratio Range Over the Past 10 Years
Min: 0.84 Med: 1.65 Max: 7.95
Current: 0.87
During the past 13 years, Nova Eye Medical's highest PS Ratio was 7.95. The lowest was 0.84. And the median was 1.65.
ELXMF's PS Ratio is ranked better than 83.23% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs ELXMF: 0.87
Nova Eye Medical Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Nova Eye Medical was 2.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -20.70% per year.
During the past 13 years, Nova Eye Medical's highest 3-Year average Revenue per Share Growth Rate was 18.50% per year. The lowest was -47.20% per year. And the median was 0.40% per year.
Back to Basics: PS Ratio
Nova Eye Medical (OTCPK:ELXMF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nova Eye Medical PS Ratio Related Terms
Nova Eye Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nova Eye Medical's Share Price of today is $0.01431.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nova Eye Medical (ELXMF) has a PS Ratio of 0.18 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nova Eye Medical and its competitors. This is 89% below median its historical median of 1.65. Over the past decade, Nova Eye Medical's PS Ratio has ranged from 0.84 to 7.95. According to the industry distribution chart, Nova Eye Medical ranks #135 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Nova Eye Medical's PS Ratio too high?
Nova Eye Medical's current PS Ratio of 0.18 is 89% below median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 7.95. The Medical Devices & Instruments industry median PS Ratio is 2.94. Nova Eye Medical's value of 0.18 is 93.9% below this industry median. Based on the distribution chart, Nova Eye Medical ranks #135 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nova Eye Medical has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #135 out of 805 companies for PS Ratio. This places Nova Eye Medical in the top 17% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.94. Nova Eye Medical's value of 0.18 is 93.9% below this benchmark. Historically, Nova Eye Medical's own PS Ratio has ranged from 0.84 to 7.95 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 2.94, Nova Eye Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current PS Ratio of 0.18 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current PS Ratio is 0.18, which is 89% below median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current PS Ratio of 0.18. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current PS Ratio is 0.18, which is 89% below median its 10-year median of 1.65 and 93.9% below the Medical Devices & Instruments industry median of 2.94. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current PS Ratio is 0.18 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
PS Ratio: 0.18 (89% below median its 10-year median of 1.65)
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
Industry Position: 93.9% below the Medical Devices & Instruments median (#135 of 805)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ELXMF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
